MAP2K7 and metastatic melanoma: The phase 3 IMspire 150 trial (NCT02908672) combined atezolizumab, an anti-PD-L1 monoclonal antibody, with the BRAF/MEK inhibitor combination vemurafenib and cobimetinib in patients with BRAFV600-mutant metastatic melanoma [42].